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A B S T R A C T
Although the kidney was initially thought to be the sole organ responsible for the production of 1,25(OH)2D via
the enzyme CYP27b1, it is now appreciated that the expression of CYP27b1 in tissues other than the kidney is
wide spread. However, the kidney is the major source for circulating 1,25(OH)2D. Only in certain granulomatous
diseases such as sarcoidosis does the extra renal tissue produce sufficient 1,25(OH)2D to contribute to the cir-
culating levels, generally associated with hypercalcemia, as illustrated by the case report preceding the review.
Therefore the expression of CYP27b1 outside the kidney under normal circumstances begs the question why, and
in particular whether the extra renal production of 1,25(OH)2D has physiologic importance. In this chapter this
question will be discussed. First we discuss the sites for extra renal 1,25(OH)2D production. This is followed by a
discussion of the regulation of CYP27b1 expression and activity in extra renal tissues, pointing out that such
regulation is tissue specific and different from that of CYP27b1 in the kidney. Finally the physiologic significance
of extra renal 1,25(OH)2D3 production is examined, with special focus on the role of CYP27b1 in regulation of
cellular proliferation and differentiation, hormone secretion, and immune function. At this point the data do not
clearly demonstrate an essential role for CYP27b1 expression in any tissue outside the kidney, but several ex-
amples pointing in this direction are provided. With the availability of the mouse enabling tissue specific de-
letion of CYP27b1, the role of extra renal CYP27b1 expression in normal and pathologic states can now be
addressed definitively.
1. Introduction
The classic paradigm for vitamin D production and metabolism in
which vitamin D is made in the skin, converted to its major circulating
form 25hydroxy vitamin D (25OHD) in the liver, and to 1,25 dihy-
droxyvitamin D (1,25(OH)2D) in the kidney has undergone major re-
visions with the findings that cells other than epidermal keratinocytes
have the capability of producing vitamin D following UVB exposure
(Vantieghem et al., 2006), that several 25OHD hydroxylases exist and
not only in the liver (Jones et al., 2014), and that numerous tissues
other than the kidney produce 1,25(OH)2D, the subject of this review.
When Fraser and Kodicek (Fraser and Kodicek, 1970) first identified the
kidney as the source of 1,25(OH)2D in 1971, it was originally thought to
be the sole source. Indeed two studies examining the conversion of
radiolabeled 25OHD to 1,25(OH)2D in anephric rats failed to detect any
formation of 1,25(OH)2D (Reeve et al., 1983; Shultz et al., 1983).
However, when anephric rats are pregnant, 1,25(OH)2D is produced
(Gray et al., 1979). Similarly a case report of a woman with chronic
kidney disease who showed an increase in 1,25(OH)2D when pregnant
was published (Turner et al., 1988), and the human placenta was shown
to be capable of 1,25(OH)2D production (Weisman et al., 1979).
Moreover, studies in anephric humans (Lambert et al., 1982; Dusso
et al., 1988) and pigs (Littledike and Horst, 1982) that were not preg-
nant found detectable levels of 1,25(OH)2D at baseline that could be
further increased with 25OHD or vitamin D administration. A report by
Barbour et al. (Barbour et al., 1981) of an anephric patient with sar-
coidosis with clearly detectable 1,25(OH)2D levels demonstrated a
disease state in which extra renal 1,25(OH)2D3 production occurred.
The source was soon discovered to be the activated pulmonary alveolar
macrophages from the involved lungs (Adams et al., 1983). At about the
same time, a number of investigators were finding 1,25(OH)2D pro-
duction by bone cells (Turner et al., 1980), melanocytes (Frankel et al.,
1983), and epidermal keratinocytes in vitro (Bikle et al., 1986a) and in
vivo (Bikle et al., 1994). With the cloning of the 25OHD 1α hydroxylase
(CYP27b1) in 1997 by 4 groups (Fu et al., 1997; Takeyama et al., 1997;
St-Arnaud et al., 1997; Shinki et al., 1997) came the demonstration that
the extrarenal CYP27b1 was the same as the renal CYP27b1 (Fu et al.,
1997; Jones et al., 1999). Moreover, the mutations in CYP27b1 that led
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to pseudo vitamin D deficiency resulted in absent CYP27b1 activity in
the skin (Fu et al., 1997) and placenta. The cloning also enabled the
development of molecular probes and antibodies to CYP27b1 (Zehnder
et al., 2001a; Zehnder et al., 2001b) facilitating the demonstration of its
expression in many other tissues. It soon became apparent that the
regulation of CYP27b1 activity in non-renal tissues differed from that in
the kidney. This difference in regulation is clearly demonstrated in
diseases such as sarcoidosis and other disorders that lead to unregulated
increases in circulating 1,25(OH)2D and hypercalcemia as illustrated by
the case report of a B cell lymphoma presenting with hypercalcemia
that initiates this review. Thus the demonstration of CYP27b1 in tissues
that were not obviously involved in bone mineral metabolism but
which also expressed the vitamin D receptor raised the question of its
physiologic role in these extrarenal sites. This question has started to be
addressed with the development of a mouse model in which CYP27b1
has been deleted (Panda et al., 2001a; Dardenne et al., 2001), and more
specifically a mouse model in which CYP27b1 can be deleted in a tissue
specific fashion (St-Arnaud et al., 2003). This chapter will address the
tissue distribution of CYP27b1, the regulation of CYP27b1 in these
cells, and the potential significance of these extra renal locations in
health and disease.
2. Case report
A 74 year old male with a past medical history of prostate cancer
status-post radical prostatectomy presented to the Emergency
Department with flank pain in 12/2015. Work up included a CT scan of
the abdomen and pelvis, which showed multiple new lytic pelvic and
spinal lesions as well as diffuse lymphadenopathy of unclear etiology.
About two weeks later, he presented with acute right arm pain that
started after he was getting out of a car. He was found to have a mid-
shaft humeral fracture and was admitted to the hospital for further
work-up and management. During this admission, a PET/CT (positron
emission tomography/computed tomography) showed progression of
disease also now involving the liver and spleen. About 1 week into this
hospital admission, he developed acute bilateral lower extremity
weakness. MRI of the spine showed T11 vertebral body compression
and extension of tumor into the anterior epidural space causing cord
compression. He underwent urgent decompressive laminectomy, and
pathology from this resection revealed high grade B-cell lymphoma
with features intermediate between diffuse large B-cell lymphoma and
Burkitt lymphoma. Chemotherapy was initiated, and he received 2 cy-
cles of R-EPOCH (rituximab in combination with etoposide, prednisone,
Fig. 1. Increased expression of CYP27B1 in the infiltrating tumor and osteoblasts, osteocytes, and osteoclasts of adjacent bone. The upper panels show the tumor, with H&E staining on
the left and a serial section immunostained for CYP27b1 on the right. The expression of CYP27b1 is depicted by the brown color. The lower panels demonstrate the strong staining for
CYP27b1 in the osteoblasts lining the bone (lower left panel), osteocytes close to the surface of bone (lower left panel), and osteoclasts (arrow in lower right panel). The 20×
bar= 50 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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vincristine, cyclophosphamide, and doxorubicin) and intrathecal
methotrexate. On the first day of chemotherapy, his corrected calcium
was 12.8, PTH 1.1 pg/ml (ref 15–88 pg/mL), PTH-related peptide
13 pg/ml (ref 14–27 pg/ml), and 25-hydroxyvitamin D 21.8 ng/ml (ref
25–50 ng/mL). 1,25-dihydroxyvitamin D was not measured at the time.
Zometa was recommended by Oncology for treatment of pathological
fractures. Over the next five months, he completed four additional cy-
cles of R-EPOCH and one additional dose of Zometa. Repeat PET/CT
showed continued progression of lymphoma. About three months fol-
lowing last cycle of chemotherapy (9/2016), he was admitted for al-
tered mental status. He was residing in a skilled nursing facility and was
noted to be more confused. Labs were notable for corrected calcium of
16.6 mg/dL. He received intravenous fluids, calcitonin and Zometa,
both of which were given to reduce the contribution of bone resorption
to the hypercalcemia. He was not taking vitamin D or calcium sup-
plements. The following day his corrected calcium improved to
13.6 mg/dL. Other labs were notable for creatinine 0.8mg/dL, phos-
phorus 2.6 mg/dL (ref 2.5–4.5 mg/dL), PTH 2.9 pg/ml (ref 15–88 pg/
ml), PTH-related peptide 16 pg/ml (ref 14–27 pg/ml), alkaline phos-
phatase 84 U/L (ref 40–125 U/L), TSH 1.80 uU/mL (ref 0.4–6 uU/mL),
25-hydroxyvitamin D 25 ng/mL (ref 25–50 pg/ml). Subsequent im-
munohistochemical staining for 1 alpha hydroxylase (CYP27B1) in
surgical tissue from the T11 mass resection was strongly positive both
for the lymphoma and the adjacent osteoblasts and osteoclasts (Fig. 1).
The etiology of the hypercalcemia was clearly related to the elevated
1,25-dihydroxyvitamin D production from the tumor, although the
PTHrP was also not suppressed and was possibly playing a role. About
1.5 weeks into his hospitalization, the patient received palliative che-
motherapy with rituximab, gemcitabine and oxaliplatin (R-Gem-Ox).
He received a total of 2 cycles. He was also started on prednisone to
reduce the burden of cells overproducing 1,25(OH)2D. A lower dose of
20mg daily was chosen due to concerns of immunosuppression with
concurrent chemotherapy. Two weeks into steroid therapy and after
another dose of Zometa, his prednisone was increased to 40mg daily
given he continued to have hypercalcemia as well as elevated
1,25(OH)2D (82 pg/mL). One month into steroid therapy, he developed
muscle weakness, concerning for steroid myopathy, and his prednisone
was tapered back down to 20mg daily with plans to completely taper
off. However, his calcium was starting to increase again, so prednisone
was increased back to 40mg daily. A follow-up PET/CT confirmed no
response to chemotherapy (Fig. 2). The patient was also experiencing
functional and cognitive decline, prompting transition to hospice. He
expired on December 14, 2016. His hospital course is shown in Fig. 3
with respect to serum calcium levels.
Although this review will emphasize the physiologic role of extra
renal CYP27b1, this case report emphasizes the pathologic role it can
play. As indicated in this case report, efforts to control the pathologic
expression of CYP27b1 include efforts to restrict bone resorption as
with potent bisphosphonates such as Zometa (zoledronate), gluco-
corticoids such as prednisone that suppress cells often of the hemato-
poietic lineage such as lymphomas or macrophages that may produce
1,25(OH)2D in an uncontrolled fashion, and antifungal drugs such as
ketoconazole that directly inhibit the CYP27b1.
3. Tissue distribution of CYP27b1
Table 1 lists the tissues, and the cells within those tissues, in which
CYP27b1 expression has been identified. The list is growing, and is
likely not complete. The biologic function of CYP27b1 in many of these
tissues is not clear.
3.1. Epithelia
Epithelia form the largest group of cells that have been shown to
produce 1,25(OH)2D3 and/or express CYP27b1. These cells provide the
barrier between the inside environment of the body and the outside, the
maintenance of which is likely one important function for CYP27b1 in
these cells. The archetype cell is the epidermal keratinocyte, which we
(Bikle et al., 1986a) showed over 30 years ago to be a very high ex-
presser of CYP27b1, higher in fact than the kidney. Based on calcula-
tions from 1,25(OH)2D production by perfused pig skin we (Bikle et al.,
1994) determined that epidermal production of 1,25(OH)2D could ac-
count for all the circulating 1,25(OH)2D found in anephric patients (or
pigs) in the basal state or after supplementation with vitamin D or
25OHD. However, most if not all 1,25(OH)2D produced by the epi-
dermis is used for autocrine or paracrine purposes with little con-
tribution to the circulation even in hyperproliferative conditions such
as psoriasis in which the expression of CYP27b1 is increased
(Sumantran et al., 2016). This is likely because of the rapid and ex-
tensive induction of CYP24 in these cells (Sumantran et al., 2016),
which limits the amount of secreted 1,25(OH)2D. However, in certain
dermal conditions associated with inflammatory infiltrates such as slack
skin disease, a T cell lymphoproliferative disease (Karakelides et al.,
2006), and subcutaneous fat necrosis of the newborn (Farooque et al.,
2009) the blood levels of calcium and 1,25(OH)2D increase in part due
to the poorly regulated CYP27b1 activity of the inflammatory cells in
the skin but not from the epidermal keratinocytes. In vitro, CYP27b1
activity as well as VDR levels decline as the keratinocytes differentiate
(Pillai et al., 1988), results consistent with observations that the highest
expression of both CYP27b1 (Zehnder et al., 2001a) and VDR (Milde
et al., 1991; Stumpf et al., 1984) is found in the stratum basale, al-
though both are found in the more differentiated layers as well. As will
be discussed in the section dealing with function, 1,25(OH)2D plays a
major role in regulating epidermal proliferation and differentiation (34)
providing an effective barrier to the environment. Deletion of CYP27b1
disrupts this process (Bikle, 2004).
Subsequent to these initial observations in epidermal keratinocytes,
CYP27b1 expression and activity have been found in most epithelia
where it has been sought. These tissues include the prostate (Hsu et al.,
2001; Chen, 2008), colonic mucosa (Zehnder et al., 2001a; Bareis et al.,
2001; Tangpricha et al., 2001; Bises et al., 2004; Lechner et al., 2007),
mammary epithelium (Segersten et al., 2005), cervical epithelium
(Friedrich et al., 2002), endometrium (Agic et al., 2007; Vigano et al.,
2006), various ocular barrier cells (Alsalem et al., 2014), and sinonasal
epithelial cells (Sultan et al., 2013). A common feature of these cells is
their barrier function, in particular to infectious organisms, which will
be discussed when their role in innate immunity is described. As in the
skin when these tissues are involved in inflammatory processes
CYP27b1 expression may increase, and in some cases results in the
entry of 1,25(OH)2D into the circulation. This was well demonstrated in
patients with Crohns Disease, 42% of whom had elevated serum levels
of 1,25(OH)2D associated with increased expression of CYP27b1 in
their intestinal mucosa (Abreu et al., 2004) as well as in a mouse model
of inflammatory bowel disease (Liu et al., 2008). Increased CYP27b1
expression relative to normal tissue is also found in endometriosis (Agic
et al., 2007; Vigano et al., 2006). The increased expression of CYP27b1
in these tissues is likely due to stimulation of the CYP27b1 by in-
flammatory cytokines, regulation that will be discussed subsequently.
Although the impact of the increased CYP27b1 expression is not clear, a
recent publication in which monocytes overexpressing CYP27b1 were
targeted to DSS induced colitis demonstrated improvement in this
mouse model (Li et al., 2015), and deletion of CYP27b1 from these cells
increased the susceptibility to DSS induced colitis (Liu et al., 2008).
Increased CYP27b1 expression is also found in the early stages of
malignancy in many of these epithelia. Examples include both basal cell
(Mitschele et al., 2004) and squamous cell (Reichrath et al., 2004)
carcinoma, breast cancer (Segersten et al., 2005), colon cancer (Bareis
et al., 2001; Tangpricha et al., 2001; Ogunkolade et al., 2002), prostate
cancer (although malignancy appears to reduce CYP27b1 expression
and activity in these cells) (Hsu et al., 2001; Chen, 2008), cervical
cancer (Friedrich et al., 2002), lung cancer (Yokomura et al., 2003;
Mawer et al., 1994), and endometrial cancer (Becker et al., 2007). This
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observation suggests a role for CYP27b1 in regulating proliferation and
differentiation of these tissues, reducing tumor progression (prostate
cancer being a possible exception). Support for this concept comes from
a recent study in which CYP27b1 was deleted from cells of a breast
cancer model, resulting in acceleration of tumorigenesis (Li et al.,
2016). However, these cancers are also associated with alternatively
spliced forms of CYP27b1, which may have less or no 1α hydroxylase
activity and may block that of intact CYP27b1 as has been shown in
proximal tubule cells (Wu et al., 2007). Such alternatively spliced forms
have been demonstrated in breast (Cordes et al., 2007; Fischer et al.,
2007a), endometrium (Becker et al., 2007), keratinocytes (Seifert et al.,
2009), lung (Radermacher et al., 2006), and cervix (Radermacher et al.,
2006; Friedrich et al., 2003). Moreover, the increase in CYP27b1 is
often accompanied by an increase in CYP24A1, which would counter
Fig. 2. Whole body PET/CT. These show the results after 6 cycles of R-EPOCH on the left and 2 cycles of R-GEM-OX on the right. The black regions show the increased uptake of the
fluordeoxyglucose used as the tracer for the PET/CT studies that signify the increased metabolic activity of the tumor.
Fig. 3. Hospital course of the patient. The upper limits of calcium in this hospital are 10.5 mg/dl. Levels above 13mg/dl are generally associated with altered mental status to coma and
require emergency treatment as in this case.
D.D. Bikle et al. Bone Reports 8 (2018) 255–267
258
the increased endogenous production of 1,25(OH)2D as shown in breast
cancer (Townsend et al., 2005), colon cancer (Bareis et al., 2001), lung
cancer (Jones et al., 1999), and endometrial cancer (Agic et al., 2007).
As tumors become less differentiated their CYP27b1 expression gen-
erally decreases (Bareis et al., 2001). This has been associated with
increased promoter hypermethylation of CYP27b1 in a substantial
number of breast cancers (Shi et al., 2002) and prostate tumors
(Khorchide et al., 2005). Other studies suggest that the CYP27b1 pro-
moter is down regulated by NFκB (Sakamoto et al., 2009) (Ebert et al.,
2004), the expression of which is increased in many cancers surrounded
by an inflammatory infiltrate (Townsend et al., 2005).
3.2. Placenta
As noted previously, the placenta was the first clearly identified
extra renal source of 1,25(OH)2D production. CYP27b1 is expressed in
both the maternal decidual stromal cells and the fetal trophoblasts
(Weisman et al., 1979; Zehnder et al., 2001a; Delvin et al., 1985; Diaz
et al., 2000; Zehnder et al., 2002a). During pregnancy the rise in ma-
ternal 1,25(OH)2D levels is due to production by the maternal portion
of the placenta, as 1,25(OH)2D, unlike 25OHD, does not readily cross
the placenta. This was well demonstrated in a study of Hannover pigs
which lack a functional CYP27b1. During pregnancy there was no rise
in serum 1,25(OH)2D despite heterozygote fetuses (Lachenmaier-Currle
et al., 1989), which are capable of producing their own 1,25(OH)2D
(Wieland et al., 1980). CYP27b1 expression increases during early
pregnancy in both the trophoblasts and decidua, but not the en-
dometrium (Vigano et al., 2006; Evans et al., 2004a). Unlike most tis-
sues the rise in CYP27b1 expression is not accompanied by an increased
expression of CYP24a1 (Evans et al., 2004a), which actually shows an
increase in methylation of its promoter (Novakovic et al., 2009), pre-
sumably suppressing its expression. Deletion of CYP27b1 is associated
with uterine hypoplasia and infertility in female mice (Panda et al.,
2001a). Preeclampsia, a condition developing mid pregnancy and
marked by hypertension is associated with a reduction in serum
1,25(OH)2D. Trophoblasts taken from preeclamptic placentae show
decreased CYP27b1 activity and response to IGF1, which is also re-
duced in these patients (Diaz et al., 2002). However, other investigators
observed an increase in CYP27b1 expression in preeclamptic placentae
(Fischer et al., 2007b), suggesting a disparity between mRNA levels and
function of the protein product as would happen if the increase in
mRNA represented alternatively spliced forms of CYP27b1.
3.3. Bone
Bone cells were the next cell type to be identified as expressing
CYP27b1 (Turner et al., 1980). The importance of this observation re-
mained ignored for decades as the prevailing dogma was that vitamin D
signaling in bone was minimal at best, in that the rickets of the
CYP27b1 and Vdr knockouts could be corrected with a diet high in
calcium and phosphate (Dardenne et al., 2003; Amling et al., 1999).
However, a more extensive evaluation of the skeleton of these knock-
outs individually and in combination demonstrated that even when
hypocalcemia and secondary hyperparathyroidism are prevented by the
rescue diet not all changes in osteoblast number, mineral apposition
rate and bone volume are rescued (Panda et al., 2004). In particular, the
width of the growth plate remained increased in the Cyp27b1 knockout
and double knockout of both Cyp27b1 and Vdr, the trabecular bone was
markedly osteopenic with decreased mineral apposition rates in both
cortical and trabecular bone, and alkaline phosphatase expression was
reduced, all signifying decreased osteoblast number or activity. Osteo-
clast numbers in the trabeculae were likewise reduced as was expres-
sion of Rankl. In vitro, bone marrow stromal cell (BMSC) cultures from
these animals demonstrated reductions in colony forming units and
mineralized nodules. Such findings stimulated a reexamination of the
role of Cyp27b1 in bone. Cyp27b1 is expressed in all bone cell types
including chondrocytes (Pedrozo et al., 1999; Panda et al., 2001b),
mesenchymal stem cells (MSC) (osteoprogenitors from bone) (Zhou
et al., 2010; Geng et al., 2011a), osteoblasts (van Driel et al., 2006;
Atkins et al., 2007), osteoclasts (Kogawa et al., 2010), and possibly
osteocytes (shown in an osteocyte cell line MLO-A5) (Turner et al.,
2014). The endogenously produced 1,25(OH)2D when these cells are
treated with 25OHD stimulates their differentiation, and in the case of
the MSC blocks their differentiation. Knockdown of Cyp27b1 with
siRNA in MSC and osteoblasts blocked the ability of 25OHD to induce
their differentiation (Geng et al., 2011a; Atkins et al., 2007). However,
although 25OHD stimulated osteoclast differentiation from peripheral
blood mononuclear cells (PBMC), it reduced the resorptive activity of
the osteoclasts that formed. On the other hand, when splenocytes were
used as the source of osteoclast progenitors, cells from CYP27b1
knockout animals were fewer and smaller but on a per cell basis had
increased resorptive capacity (Reinke et al., 2016). Similar findings had
been shown for Vdr knockout splenocytes (Kogawa et al., 2010). The
cell specific deletion of Cyp27b1 from chondrocytes shows a reduction
in osteoclastogenesis in the primary spongiosa associated with de-
creased Rankl expression, an increase in trabecular bone volume in the
metaphysis of neonatal long bones, and a reduction in angiogenesis
associated with a reduction in Vegf expression. The width of the hy-
pertrophic zone of the growth plate was widened on embryonic day
15.5, but these changes in the growth plate did not persist (St-Arnaud
et al., 2003; Naja et al., 2009). Some of these changes may have been
secondary to the increase in circulating Fgf23 in these mice (St-Arnaud
et al., 2003). When Cyp27b1 was overexpressed in chondrocytes the
opposite effects to that of the knockout were observed (Naja et al.,
2009).
Table 1
Tissues and cells expressing CYP27b1.
A. Epithelia
1. Epidermis and hair follicles (keratinocytes)
2. Prostate
3. Colon epithelium
4. Mammary epithelium
5. Uterus (endometrium)
6. Corneal epithelium
7. Retinal pigment epithelium
8. Ciliary body epithelium
9. Sinonasal epithelium
B. Placenta
1. Decidua
2. Trophoblasts
C. Bone
1. Osteoblasts
2. Osteoclasts
3. Osteocytes
4. Chondrocytes
D. Immune system
1. Macrophages
2. Monocytes
3. Dendritic cells
4. T cells
5. B cells
E. Endocrine glands
1. Parathyroid gland
2. Pancreatic islets
3. Thyroid gland
4. Adrenal medulla
5. Testes
6. Ovary
F. Other
1. Brain
2. Liver
3. Endothelia
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3.4. Cells of the immune system
Although sarcoid tissue was clearly identified as the extrarenal
source of 1,25(OH)2D in 1981 (Barbour et al., 1981), the pulmonary
alveolar macrophage from patents with sarcoidosis 1983 was perhaps
the clearest demonstration that the macrophage was responsible
(Adams et al., 1983). Unlike the kidney, the production of 1,25(OH)2D
by macrophages was substrate dependent (Adams et al., 1983) and not
product limited (Adams and Gacad, 1985), and the CYP27b1 activity in
macrophages was clearly not regulated by PTH and calcium (Insogna
et al., 1988). Part of the lack of regulation is due to truncated versions
of CYP24a1 which do not have enzymatic activity and so do not cata-
bolize 1,25(OH)2D within the macrophage allowing it to enter the
circulation (Ren et al., 2005). This truncated form of CYP24a1, which
includes the substrate binding domain but not the mitochondrial tar-
geting sequence, is postulated to act as a dominant negative form of
CYP24a1, binding 1,25(OH)2D within the cytoplasm and preventing its
catabolism (Ren et al., 2005). Both intact CYP24a1 and the truncated
variant are induced in macrophage cell lines (HD-11 and THP-1), but
CYP24a1 activity is not increased. As mentioned earlier, at least in the
placenta the expression of CYP24a1 does not increase in parallel with
the increase in CYP27b1 due to methylation (and inhibition) of its
promoter, possibly also contributing to the decreased regulation of
1,25(OH)2D production by these cells (Novakovic et al., 2009).
Extrarenal CYP27b1 expression in macrophages is not limited to
sarcoidosis. CYP27b1 expression has been found in pulmonary alveolar
macrophages from patients with tuberculosis (Barnes et al., 1989),
coccidiomycosis and cryptococcosis (Ali et al., 1999), the peritoneum
from individuals undergoing peritoneal dialysis (Bacchetta et al., 2013)
and from patients with peritonitis (Hayes et al., 1987), from the syno-
vium of patients with inflammatory arthritis (Hayes et al., 1992),
granulomata in the colon of patients with Crohn's disease (Abreu et al.,
2004), granulomata in the skin of a patient with slack skin disease (a T
cell lymphoproliferative disorder (Karakelides et al., 2006)), sub-
cutaneous fat necrosis of the newborn (Farooque et al., 2009; Finne
et al., 1988), granulomata within lymph nodes (Zehnder et al., 2001a),
circulating monocytes from patients with chronic renal failure (Dusso
et al., 1991), foreign body granulomata (Hindi et al., 2015) and normal
monocytes activated in vitro (Gyetko et al., 1993). Kallas and Hewison
provide a well referenced table of these infectious and inflammatory
causes of elevated 1,25(OH)2D production (Kallas et al., 2010).
Dendritic cells (DC) require activation to express CYP27b1 (Fritsche
et al., 2003). These are the principal antigen presenting cells to the T
cells, a key feature of adaptive immunity. 1,25(OH)2D suppresses the
maturation of DC and increases their expression of IL-10 that together
increase tolerogenesis with reduction of the differentiation of Th1 and
Th17 lymphocytes and increased differentiation of Th2 and Treg lym-
phocytes (Penna and Adorini, 2000). Th lymphocytes also express
CYP27b1 as well as the VDR when activated (Sigmundsdottir et al.,
2007; Bhalla et al., 1983). 1,25(OH)2D inhibits the proliferation of
these cells as well as their production of cytokines such as IL-2, IFNγ,
and TNF, while promoting the expression of Th2 and Treg cytokines
such as IL-3, IL-4, IL-5, and IL-10 (Lemire et al., 1985; Boonstra et al.,
2001). B lymphocytes also express CYP27b1 (Chen et al., 2007).
1,25(OH)2D reduced their proliferation and differentiation into plasma
cells thus reducing antibody production (Chen et al., 2007). The role of
endogenous 1,25(OH)2D production in T and B cells was recently tested
by examining the response of these cells to OVA induced sensitization
and intestinal infection with Heligmosomoides polygyrus, two means of
inducing an IgE and IgG1 response (Lindner et al., 2017). In the global
CYP27b1 knockout, IgE and IgG1 were increased more than controls in
the OVA-sensitization model, but only IgE in the Heligmosomoides
polygyrus model. When CYP27b1 was selectively deleted in either the T
or B lymphocytes significant increases in IgE and antibody secreting
cells after OVA challenge were seen only in the T cell specific knockout.
3.5. Endocrine glands
Several endocrine glands, the parathyroid gland and pancreatic is-
lets in particular, whose products are regulated by 1,25(OH)2D, also
express CYP27b1 (Zehnder et al., 2001a; Bland et al., 2004; Correa
et al., 2002; Ritter et al., 2012; Ritter et al., 2006). Expression of
CYP27b1 appears to be greater in parathyroid adenomas, whether
primary or secondary to renal failure, compared to normal glands
(Correa et al., 2002; Segersten et al., 2002), and is preferentially ex-
pressed in oxyphil compared to chief cells (Ritter et al., 2012). When
sequenced, none of these adenomas expressed inactivating mutations in
CYP27b1 to suggest that CYP27b1 was functioning as a tumor sup-
pressor gene (Lauter and Arnold, 2009). Malignant pancreatic tissue
and cell lines derived from such tissue express CYP27b1 at levels
comparable to normal tissue (Schwartz et al., 2004). Polymorphisms in
CYP27b1 have been associated with increased risk of type 1 diabetes
mellitus (Bailey et al., 2007), although it is unclear whether this link is
due to regulation of insulin secretion or to the immune response leading
to this form of diabetes. The thyroid has also been shown to express
CYP27b1 (Clinckspoor et al., 2012), and this expression is increased in
papillary carcinoma of this gland (Khadzkou et al., 2006), although
CYP27b1 expression is decreased in metastases (Clinckspoor et al.,
2012). However, unlike the parathyroid gland and pancreatic islet, it is
unclear whether 1,25(OH)2D influences hormone secretion from the
thyroid gland. CYP27b1 protein has been detected in the adrenal me-
dulla by immunohistochemistry (Zehnder et al., 2001b), although no
reports of 1,25(OH)2D3 regulated cathecholamine production or altered
CYP27b1 expression in patients with pheochromocytoma have been
published. The testes express CYP27b1 (Fu et al., 1997). Using the
promoter of CYP27b1 to drive a luciferase promoter, Anderson et al.
(Anderson et al., 2008) localized CYP27b1 expression in both Leydig
and Sertoli cells of the testes, results subsequently confirmed (Blomberg
Jensen et al., 2010). CYP27b1 expression has also been found in the
ovary (Evans et al., 2004b) and ovarian cancer (Fischer et al., 2009;
Brozyna et al., 2015) where its expression is negatively correlated with
tumor growth. Dysgerminomas of the ovary have a much greater ex-
pression of CYP27b1 than normal ovarian tissue (Evans et al., 2004b).
This has significance in that hypercalcemia is known to occur with
dysgerminomas, and a recent case report attributed the hypercalcemia
to increased 1,25(OH)2D levels in a patient with an ovarian dysgermi-
noma (Hibi et al., 2008).
3.6. Other tissues
The liver, well known to be the major site for 25OHD production,
has also been shown to express CYP27b1 (Hollis, 1990), which at least
in the rat appears to disappear postnatally (Takeuchi et al., 1994). This
observation has received little further investigation following these
initial and early publications.
Expression of CYP27b1 in the brain was also a surprise result of our
initial tissue screen for CYP27b1 (Fu et al., 1997). Subsequent locali-
zation studies have demonstrated expression in the cerebellum and
cerebral cortex (Zehnder et al., 2001a), and, in particular, in Purkinje
cells (Anderson et al., 2008). Glioblastomas show increased CYP27b1
expression (Fischer et al., 2010) along with spliced variants of CYP27b1
(Maas et al., 2001), the significance of which is uncertain (Diesel et al.,
2003). Zehnder et al. observed CYP27b1 expression in human en-
dothelial cells and 1,25(OH)2D production by human umbilical vein
endothelial cells in vitro (Zehnder et al., 2002b). 25OHD or 1,25(OH)2D
decreased their proliferation and increased adhesion of the monocyte
cell like U937 to these cells suggesting a role in endothelial cell adhe-
sion.
4. Regulation of extrarenal CYP27b1 expression
An important feature of extrarenal CYP27b1 is that its regulation
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differs from that of the kidney, the regulation of CYP27b1 in the
proximal convoluted tubule (PCT) of the kidney to be precise. CYP27b1
in the renal PCT is controlled principally by three hormones, para-
thyroid hormone (PTH), FGF23, and 1,25(OH)2D itself responding at
least in part to changes in ambient calcium and phosphate levels (re-
view in (Jones et al., 2014)). Calcitonin regulates CYP27b1 activity in
the proximal straight tubule (Kawashima et al., 1981), but this has
received little further study. PTH stimulates CYP27b1 expression
principally by acting on its membrane receptor to promote cyclic AMP
formation, PKA activation, and enhanced binding of CCAAT box
binding protein to its proximal response element in the CYP27b1 pro-
moter (Gao et al., 2002). FGF23 inhibits CYP27b1 expression by a
mechanism involving its binding to one of several FGF receptors in
association with Klotho, activating MAPK, but the molecular events
leading to inhibition of CYP27b1 expression by this pathway are not
well defined (Strom and Juppner, 2008). Calcium and phosphate, by
regulating the secretion of PTH and FGF23 from the parathyroid glands
and bone, respectively, indirectly regulate CYP27b1 activity in the
kidney, although they also have direct effects (Omdahl et al., 1972;
Tanaka and Deluca, 1973; Bikle, 1978). 1,25(OH)2D directly inhibits
CYP27b1 expression in the kidney through a complex mechanism in-
volving VDR that brings both histone deacetylases (HDAC) and DNA
methyl transferases to the promoter of CYP27b1 inhibiting its tran-
scription (Kim et al., 2007). These feedback loops provide very tight
regulation of 1,25(OH)2D production by the PCT of the kidney, control
that differs from that of CYP27b1 in other cell types including that of
distal renal tubule cells where PTH has little effect (Bajwa et al., 2008).
Meyer et al. (2017) recently identified a region in the CYP27b1 en-
hancer region in DNA from the kidney that was responsive to PTH,
FGF23, and 1,25(OH)2D regulation. However, this region was not ac-
cessible to such regulation in the extrarenal tissues they tested in-
cluding skin and bone, but was regulated by inflammatory factors,
consistent with different regulatory mechanisms in extra renal tissues.
However, this distinction is not so precise as the genomic data would
suggest when tested directly in cells from non-renal tissues as we will
now describe.
4.1. Keratinocytes
When we (Bikle et al., 1986b) first examined the ability of PTH to
stimulate 1,25(OH)2D production by keratinocytes, we observed that
their response to PTH differed from that of the kidney in that PTH
binding to a receptor could not be demonstrated, and cyclic AMP did
not appear to be involved, although the response was potentiated by
inhibition of phosphodiesterase. Moreover, Flanagan et al. (Flanagan
et al., 2003) using a CYP27b1 promoter/luciferase reporter assay de-
monstrated PTH stimulated expression in a kidney cell line but not in
keratinocytes, suggesting that the effect of PTH may be post-tran-
scriptional. However, this construct consisted of only 1500 bp 5′ of the
promoter, and may not have contained the region of DNA that re-
sponded to PTH signaling in keratinocytes. PTH/PTHrP receptors have
subsequently been identified in the epidermis and isolated keratino-
cytes (Errazahi et al., 2004), and Muehleisen et al. (Muehleisen et al.,
2012) more recently made the surprising observation that incubation of
keratinocytes with 25OHD could induce the expression of the PTH/
PTHrP receptor. Moreover, epidermal keratinocytes produce PTHrP
(Merendino Jr et al., 1986), so conceivably keratinocyte CYP27b1 is
regulated by PTH/PTHrP, but this has not yet been demonstrated.
Likewise, the effect of FGF23 on keratinocyte CYP27b1 expression or
function has not been reported. Unlike the kidney, 1,25(OH)2D does not
directly affect CYP27b1 expression in keratinocytes. Rather,
1,25(OH)2D regulates its own levels in the keratinocyte by inducing
CYP24a1, the catabolic enzyme for 1,25(OH)2D (Xie et al., 2002).
Tumor necrosis factor-α (TNF) (Bikle et al., 1991) and interferon-γ
(IFN) (Bikle et al., 1989), on the other hand, are potent inducers of
CYP27b1 activity in the keratinocyte as is TGFβ1 (Schauber et al.,
2007). 1,25(OH)2D induces the expression TLR2 and CD14, and acti-
vation of TLR2 with a specific agonist, malp-2, but not with a TLR 4
agonist, lipopolysaccharide (LPS), induces CYP27b1 (Schauber et al.,
2007). This feed forward mechanism plays a role in both wound healing
and the response to infection as will be discussed subsequently.
4.2. Bone
CYP27b1 in human mesenchymal stem cells from bone marrow is
stimulated by PTH through mechanisms involving both the phosphor-
ylation of CREB (an acute response) and through the expression of IGF1
and the activation of its receptor (longer term response) (Geng et al.,
2011b). 25OHD increases CYP27b1 expression in these cells, but that
appears to be due to a combination of increased expression of the PTH/
PTHrP receptor (Zhou et al., 2013) and IGF1 (Zhou et al., 2010) as
1,25(OH)2D decreases the expression of CYP27b1 in these cells (Zhou
et al., 2010). Similarly, PTH stimulated osteoblasts from human bone
explants (Somjen et al., 2007), although no mechanism was evaluated.
In contrast to these results others have not found that PTH stimulated
CYP27b1 in human osteoblasts (van Driel et al., 2006) or in ROS 17/2.8
osteoblasts transfected with a 1500 bp 5′ flanking region of CYP27b1
(Turner et al., 2007). Moreover, in the latter studies the authors ob-
served a 50+ % inhibition by IGF1 and TGF-β with no inhibition by
1,25(OH)2D. However, as mentioned above, the enhancer regions reg-
ulating a gene may be at substantial distances from the promoter, so
that such studies with short constructs may be misleading.
4.3. Macrophages and monocytes
The production of 1,25(OH)2D by pulmonary alveolar macrophages
is activated by IFNγ and TNFα, but not by IFNα and IFNβ, and is in-
hibited by dexamethasone (Adams and Gacad, 1985; Pryke et al., 1990)
(Adams and Gacad, 1985). The stimulation of CYP27b1 by IFNγ may
involve increased NO production (Adams et al., 1986). Preincubation of
these cells with 1,25(OH)2D did not alter enzymatic activity indicating
no direct inhibition as in the kidney (Adams and Gacad, 1985). IL-1, IL-
2 and IL-15 also stimulate CYP27b1 activity in peripheral blood
mononuclear cells (PBMC), whereas IL-4 is suppressive (Gyetko et al.,
1993; Edfeldt et al., 2010). In contrast to Th1 cells, which produce IFNγ
and IL-2, Th2 cells produce not only IL-4 but IFNβ that increases IL-10
to decrease CYP27b1 activity (Teles et al., 2013). In other studies of
PBMC, the combination of IFNγ and either phorbol ester (PMA) or LPS
induced CYP27b1 (Stoffels et al., 2006). In these studies of PBMC the
induction of CYP27b1 was blocked by inhibition of the JAK/STAT
pathway, NFκB pathway, and p38 MAPK pathway (Stoffels et al., 2006).
The same group then demonstrated in peritoneal macrophages (PM)
that IFNγ stimulation of CYP27b1 required C/EBPβ and was inhibited
by knocking out STAT1α or Interferon regulatory factor 1 (IRF1). LPS
stimulates these pathways through TLR4 in association with the cor-
eceptor CD14 (Stoffels et al., 2006), a point that will become important
when the functional role of extra renal production of 1,25(OH)2D3 is
discussed, and a difference from the role of TLR2 in keratinocytes
(Vidya et al., 2017). Similar results were obtained with the macrophage
cell line THP-1 (Overbergh et al., 2006). In a v myc transformed
myelomonocytic cell line (HD-11), Adams et al. (1994) demonstrated
stimulation of 1,25(OH)2D production by LPS and IFNγ, and failure of
PTH or calcium and phosphate to regulate CYP27b1 activity. Both
PBMC and PM express FGF receptors and Klotho, and respond to FGF23
with a reduction in CYP27b1 expression likely through the MAPK
pathway similar to that in the kidney (Bacchetta et al., 2013).
4.4. Parathyroid gland
The parathyroid gland expresses both FGF receptors and Klotho
(Silver and Naveh-Many, 2012). Unlike the kidney, FGF23 stimulates
CYP27b1 expression in the parathyroid gland (Ritter et al., 2012;
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Krajisnik et al., 2007). Activation of the calcium sensing receptor in the
parathyroid gland either by calcium or cinacalcet also increases
CYP27b1 expression (112). Both FGF23 (Silver and Naveh-Many, 2012)
and cincalcet (Ritter et al., 2012) reduce PTH secretion suggesting a
link between PTH secretion and CYP27b1 expression. However, as yet
unpublished observations by Chang et al. have shown that PTH sti-
mulates CYP27b1 activity just as parathyroid gland specific knockout of
CYP27b1 markedly increases PTH secretion (Chang et al., personal
communication) indicating an intracrine feedback loop in the para-
thyroid gland between PTH and CYP27b1.
5. Function of extra renal CYP27b1
The kidney appears to be the major if not the sole source of circu-
lating 1,25(OH)2D, so the role of extrarenal CYP27b1 needs to be ad-
dressed. Two considerations come to mind. First the substrate for
CYP27b1, namely 25OHD, circulates at much higher concentrations
than 1,25(OH)2D. Although essentially all of the 25OHD is protein
bound (99.97%) (Bikle et al., 1986c), some cells express a mechanism
involving megalin/cubilin that enables them to transport the 25OHD
bound to its major carrier vitamin D binding protein (DBP) into the cell
(Nykjaer et al., 1999). This was originally discovered in the kidney,
enabling the kidney to recover DBP bound 25OHD from the glomerular
filtrate, but megalin/cubilin expression has also been observed in a
wide number of tissues including the placenta, parathyroid gland,
choroid plexus, thyroid, intestinal epithelium, endometrium, epidi-
dymis (reviewed in (Christensen and Birn, 2002)), macrophages
(Adams et al., 2007) and osteoblasts (Atkins et al., 2007). However,
demonstration of uptake of DBP bound 25OHD by these cells has not
been established in most cases. Second, circulating 1,25(OH)2D levels
are tightly controlled, whereas the extrarenal CYP27b1 production
operates under different controls and so may be more adaptable to the
specific needs of that particular cell. That said the roles of extrarenal
CYP27b1 can be considered to fall into three broad categories: the
regulation of cellular proliferation and differentiation, the regulation of
hormone secretion, and the regulation of immune function both innate
and adaptive. These are not mutually exclusive. In all cases the role of
endogenously produced 1,25(OH)2D is that of a ligand for the vitamin D
receptor (VDR) expressed in nearly every cell in the body.
5.1. Regulation of proliferation and differentiation
Epidermal keratinocytes provide an excellent model to evaluate the
ability of 1,25(OH)2D to regulate proliferation and differentiation in a
normal cell. 1,25(OH)2D promotes the differentiation of keratinocytes
while inhibiting their proliferation (Bikle and Pillai, 1993; Bikle, 2012).
In the epidermis proliferation occurs in the basal layer, and as the
keratinocytes move out of the basal layer differentiation is initiated. As
the keratinocytes move from one layer of epidermis to the next, dif-
ferentiation proceeds in a sequential fashion ultimately resulting in the
enucleated corneocyte enmeshed in a lipid rich matrix that provides the
barrier function. 1,25(OH)2D is involved in all steps of this process in
that it limits proliferation in the basal layer while inducing in a se-
quential pattern the expression of genes whose products ultimately
produce the permeability barrier. Included in the development of the
permeability barrier is the production of antimicrobial peptides such as
cathelicidin, important for the innate immune response in the epidermis
(Schauber et al., 2007) and other epithelial and immune cells as will be
discussed. CYP27b1 like VDR is found throughout the epidermis, al-
though expression appears to be higher in the basal layer of the epi-
dermis (Zehnder et al., 2001a; Milde et al., 1991; Stumpf et al., 1984).
The CYP27b1 null mouse has increased keratinocyte proliferation, de-
creased epidermal differentiation, fails to form the calcium gradient
within the epidermis important for the differentiation process, and is
limited in the ability to reform the permeability barrier following dis-
ruption (Bikle et al., 2004). Moreover, these mice are less resistant to
infection (Muehleisen et al., 2012) and have a blunted innate immune
response to wounding (Schauber et al., 2007).
5.1.1. Psoriasis
Psoriasis is an example of a hyperproliferative disease of the skin for
which analogs of 1,25(OH)2D and 1,25(OH)2D itself have proven suc-
cessful (Bruce et al., 1994). Psoriasis is a chronic, generalized, and scaly
erythematous dermatosis thought to be due to a Th1 or Th17 mediated
immune reaction to as yet unidentified antigens in the skin that may
cause or at least is accompanied by increased proliferation and de-
creased differentiation of the keratinocytes in the epidermis.
1,25(OH)2D and its analogs likely work by inhibiting the inflammatory
component of the disease via a direct action on the T cells (Bagot et al.,
1994) as well as by reducing keratinocyte proliferation and enhancing
their differentiation (Kragballe and Wildfang, 1990). Given the in-
creased expression of CYP27b1 in these cells, topical treatment with
25OHD may also prove effective, but to my knowledge results with this
form of therapy have not been reported.
5.1.2. Cancer
As noted in the section on tissue distribution CYP27b1 is expressed
in a number of malignant tissues. Moreover, expression is often in-
creased in the early stages of tumor development but is lost as the tu-
mors dedifferentiate (Hobaus et al., 2013). Many animal studies have
demonstrated a reduction in growth in such cancers following admin-
istration of 1,25(OH)2D or its analogs (Campbell and Trump, 2017),
and epidemiologic evidence is consistent with a role for vitamin D in
preventing many of these cancers in humans (Garland et al., 1985;
Bostick et al., 1993; Kearney et al., 1996; Garland et al., 1990;
Hanchette and Schwartz, 1992). Moreover, polymorphisms in CYP27b1
have been found in hepatocellular carcinoma (Lange et al., 2013), lung
cancer (Kong et al., 2015), and prostate cancer (Gilbert et al., 2015). In
a recent study Li et al. (Li et al., 2016) deleted CYP27b1 from the
mammary epithelium in a mouse breast cancer model and demon-
strated an acceleration of tumorigenesis. However, in the CYP27b1 null
mouse we were unable to demonstrate an increase in UV induced tumor
formation using a protocol comparable to that which induced tumors in
VDR null mice (Bikle, 2013). Therefore, the role of extrarenal CYP27b1
in tumor development may be tissue specific.
5.2. Regulation of hormone secretion
5.2.1. Parathyroid hormone (PTH)
Circulating PTH levels are better correlated with 25OHD levels than
with 1,25(OH)2D levels (Vieth et al., 2003) even though it is
1,25(OH)2D that inhibits the synthesis and secretion of PTH (Demay
et al., 1992) and prevents the proliferation of the parathyroid gland
(Demay et al., 1992; Martin and Gonzalez, 2004). The expression of
CYP27b1 within the parathyroid gland could account for this ob-
servation. The parathyroid gene contains a negative VDRE through
which 1,25(OH)2D exerts its suppression (Demay et al., 1992).
1,25(OH)2D also induces the calcium sensing receptor (CaSR) in the
parathyroid gland (Canaff and Hendy, 2002), which sensitizes the
parathyroid gland to calcium inhibition. As noted previously Cheng
et al. in studies reported only in abstract form (ASBMR, 2011) have
shown that deletion of CYP27b1 from the parathyroid gland markedly
increased PTH secretion.
5.2.2. Insulin
A number of mostly case control and observational studies have
suggested that vitamin D deficiency contributes to increased risk for
types 1 and 2 diabetes mellitus (Pittas et al., 2007). In animal studies
1,25(OH)2D has been shown to stimulate insulin secretion, although the
mechanism is not well defined (Kadowaki and Norman, 1985; Lee et al.,
1994). Moreover, a recent study identified a polymorphism in CYP27b1
that predisposed to islet cell autoimmunity (Frederiksen et al., 2013).
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However, it is not clear what role the CYP27b1 in the pancreatic islet
plays in this process as diabetes mellitus is not described in the Cyp27b1
knockout. This question will be best answered with tissue specific
Cyp27b1 deletion.
5.2.3. Renin
The renin/angiotensin system is active in both heart and kidney. It
is a major regulator of blood pressure. 1,25(OH)2D is a negative reg-
ulator of renin secretion (Li et al., 2004). The Cyp27b1 knockout mouse
develops hypertension and cardiac hypertrophy with increased ex-
pression of the renin/angiotensin system in both heart and kidney.
These changes persisted even when the mice were placed on the rescue
diet to normalize their calcium, phosphate and PTH levels (Zhou et al.,
2008). Although cardiac specific deletion of VDR has been reported
showing similar cardiac changes (Gardner et al., 2013), comparable
studies have not been reported with a cardiac specific Cyp27b1
knockout.
5.2.4. Fibroblast growth factor 23 (FGF23)
FGF23 is produced primarily in bone by osteoblasts and osteocytes.
1,25(OH)2D stimulates this process, but the mechanism is not clear
(Kolek et al., 2005). Surprisingly, chondrocyte specific deletion of
Cyp27b1 reduced circulating levels of Fgf23 presumably altering an as
yet unidentified signal, possibly 1,25(OH)2D itself, from chondrocytes
to the osteoblasts/osteocytes. At this point, osteoblast/osteocyte spe-
cific Cyp27b1 deletions have not been reported.
5.2.5. Estrogen and testosterone
1,25(OH)2D regulates the expression of aromatase involved in es-
trogen metabolism in mammary tumors potentially contributing to
their antiproliferative actions (Swami et al., 2011). However, the im-
pact of 1,25(OH)2D on ovarian production of estrogen has not been
reported. 1,25(OH)2D does not alter testosterone production in the
testes (Blomberg Jensen, 2014). Female mice lacking Cyp27b1 are in-
fertile with hypoplastic uteri and loss of corpora lutea suggesting es-
trogen deficiency, but estrogen levels were not measured (Panda et al.,
2001a). Male mice lacking Cyp27b1 remain fertile.
5.3. Regulation of immune function
5.3.1. Adaptive immunity
The adaptive immune response involves the ability of T and B
lymphocytes to produce cytokines and immunoglobulins, respectively,
to specifically combat the source of the antigen presented to them by
cells such as macrophages and dendritic cells. As noted previously,
CYP27b1 expression is increased when these cells are activated.
1,25(OH)2D exerts an inhibitory action on the adaptive immune system
by suppressing the proliferation and differentiation of B-cell precursors
into plasma cells (Chen et al., 2007), inhibiting T cell proliferation and
function (Rigby et al., 1984), in particular Th1 (Lemire et al., 1995) and
Th17 (Daniel et al., 2008) cells, and shifting the balance to favor Th2
cell (Boonstra et al., 2001) and regulatory T cell (Treg) function. At
least in part these actions on T cell proliferation and differentiation
stem from actions of 1,25(OH)2D on dendritic cells to reduce their
antigen presenting capability. The ability of 1,25(OH)2D to suppress the
adaptive immune system appears to be beneficial for a number of
conditions in which the immune system is directed at self—i.e. auto-
immunity. In a number of experimental models (Adorini, 2005; Deluca
and Cantorna, 2001) including inflammatory arthritis, autoimmune
diabetes, experimental allergic encephalitis (a model for multiple
sclerosis), and inflammatory bowel disease 1,25(OH)2D administration
has prevented and/or treated the disease process. Thus local production
of 1,25(OH)2D in pulmonary alveolar macrophages, peritoneal macro-
phages, synovial macrophages, PBMC, pancreatic islets, neurons in the
brain, lung, and intestinal mucosa, all tissues which express CYP27b1,
may provide a mechanism to control the destructive immune process
that is the etiology for these disease processes.
5.3.2. Innate immunity
Innate immune responses involve the activation of toll-like re-
ceptors (TLRs) in a number of epithelial cells including those of the
epidermis, gingiva, intestine, vagina, placenta, bladder and lungs as
well as cells of the immune system including PBMC and macrophages.
TLRs are transmembrane pathogen-recognition receptors that interact
with specific membrane patterns (PAMP) shed by infectious agents that
trigger the innate immune response in the host (Medzhitov, 2007).
Activation of TLRs leads to the induction of antimicrobial peptides and
reactive oxygen species, which kill the organism. Among those anti-
microbial peptides is cathelicidin. The expression of this antimicrobial
peptide is induced by 1,25(OH)2D in both myeloid and epithelial cells
(Gombart et al., 2005; Wang et al., 2004), cells which express both VDR
and CYP27b1. The innate immune response of the macrophage, kera-
tinocyte, and placenta provide the best examples of the role of local
CYP27b1 activity to meet a local challenge. Vitamin D deficiency has
long been associated with increased risk of tuberculosis (Ustianowski
et al., 2005), and 1,25(OH)2D has long been recognized to potentiate
the killing of mycobacteria by monocytes (Rook et al., 1986). Macro-
phages when activated by mycobacterial lipopeptides through TLR2/1
heterodimers express both CYP27b1 and VDR, leading to the produc-
tion of 1,25(OH)2D from circulating 25OHD, which bound to VDR to
induce cathelicidin that enhanced killing of the mycobacterium (Liu
et al., 2006). Inadequate circulating 25OHD levels failed to support this
process (Liu et al., 2006). In keratinocytes the expression of TLR2 and
CD14, critical receptors for a number of pathogenic organisms acti-
vating the innate immune response, is increased by 1,25(OH)2D as is
the expression of cathelicidin (Schauber et al., 2007). When the skin is
wounded expression of CYP27b1 increases along with that of TLR2,
CD14, and cathelicidin (Schauber et al., 2007). These changes do not
occur in mice lacking Cyp27b1 in their epidermis (Schauber et al.,
2007). In the placenta both the maternal decidua and fetal trophoblast
produce cathelicidin in response to 1,25(OH)2D (Liu et al., 2009). When
the placentas from Cyp27b1 knockout mice were evaluated, in-
flammatory cytokine production in response to LPS was amplified
suggesting an important role for CYP27b1 in this tissue controlling the
placental response to inflammatory stimuli (Liu et al., 2011). Other
epithelia of tissues facing the outside environment must provide a
protective barrier, and it is anticipated that the innate immune system
in these tissues will likewise be regulated by local 1,25(OH)2D pro-
duction. However, this needs to be demonstrated with tissue specific
deletion of Cyp27b1.
6. Summary
CYP27b1 is expressed widely and in cells also expressing VDR.
Although the data are limited with respect to tissue specific deletions of
CYP27b1, in those tissues where this has been achieved local produc-
tion of 1,25(OH)2D has been shown to exert effects on that tissue in-
dependent of circulating 1,25(OH)2D. However, such studies are the
exception and not the rule, so that definitive data on this point will only
come from additional studies with tissue specific deletion of CYP27b1.
Should local expression of CYP27b1 be shown as critical for cell specific
functions, the potential to manipulate 1,25(OH)2D production in the
tissue of choice without incurring systemic changes in calcium home-
ostasis will be an important advance in the treatment of a variety of
diseases. These include treatment of cancers with uncontrolled pro-
liferation and disordered differentiation, better management of hy-
perparathyroidism and insulin secretion in diabetics, suppressing
renin/angiotension in hypertension, improving wound repair, limiting
tissue destruction in autoimmune diseases, and enhancing the re-
sistance to infectious organisms such as streptococcus and tuberculosis.
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